(Q36691482)

15 August 2017

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis (English)

1 reference

15 August 2017

C Leonardi

1

1 reference

15 August 2017

A Menter

2

1 reference

15 August 2017

T Hamilton

3

1 reference

15 August 2017

I Caro

4

1 reference

15 August 2017

B Xing

5

1 reference

15 August 2017

A B Gottlieb

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

27 March 2008

1 reference

British Journal of Dermatology

15 August 2017

1 reference

15 August 2017

158

1 reference

15 August 2017

5

1 reference

15 August 2017

1107-1116

1 reference

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Risk-benefit assessment of methotrexate in the treatment of severe psoriasis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Therapeutic strategies: rotational therapy and combinations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

The risk of melanoma in association with long-term exposure to PUVA.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Clinical management of psoriasis: principles and practice.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Acitretin in psoriasis: an overview of adverse effects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Oral retinoids--efficacy and toxicity in psoriasis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Malignant tumours and psoriasis: a follow-up study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

The natural history of psoriasis in 5,600 patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2408637

Long-term safety of cyclosporine in the treatment of psoriasis

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08548.X

ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group

21 January 2018

1 reference

12 December 2020

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

1 reference

12 December 2020

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis

1 reference

12 December 2020

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial

1 reference

12 December 2020

The Risk of Lymphoma in Patients with Psoriasis

1 reference

12 December 2020

Psoriasis, its treatment, and cancer in a cohort of Finnish patients

1 reference

12 December 2020

The risk of malignancy associated with psoriasis

1 reference

12 December 2020

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

1 reference

12 December 2020

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

12 December 2020

Long-term safety of cyclosporine in the treatment of psoriasis

1 reference

12 December 2020

Efficacy and safety of treatment modalities for psoriasis

1 reference

12 December 2020

10.1111/J.1365-2133.2008.08548.X

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18373710

1 reference